Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
Genzada Pharmaceuticals USA, Inc.
Ludwig Institute for Cancer Research
Jonsson Comprehensive Cancer Center
University of Wisconsin, Madison
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
Vanderbilt-Ingram Cancer Center
Wake Forest University Health Sciences
European Organisation for Research and Treatment of Cancer - EORTC
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Indiana University
University of Minnesota
Mayo Clinic
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Roswell Park Cancer Institute
Northwestern University
Northwestern University
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Scripps Health
Fred Hutchinson Cancer Center